Vitality Watch

Dossier pubmed trial early 10-sep-2026
Small or early-phase human trial or pilot study

EXPRESS: Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: a pilot single-arm trial.

Key claim: Low-dose rapamycin (1 mg/day for 4 weeks) significantly increased cerebral blood flow by over 15% across multiple brain regions and improved metabolic and inflammatory profiles in healthy middle-aged APOE4 carriers, with little CBF effect in non-carriers.

Abstract

Carriers of the apolipoprotein E4 (APOE4) allele often develop cerebrovascular dysfunction and broader systemic alterations decades before the onset of Alzheimer’s disease (AD) pathology or clinical symptoms. Early interventions that can improve these functions may help delay or slow AD progression. In this study, we repurposed rapamycin (sirolimus), an FDA-approved medication with anti-aging properties, to target APOE4 associated multisystem dysfunction. We conducted a single arm trial of low dose rapamycin (1 mg/day for 4 weeks) in cognitively normal adults aged 45 to 65 years, prior to detectable AD pathology, stratified by APOE genotype. The primary outcome was cerebral blood flow (CBF), while secondary outcomes included plasma metabolomics, inflammatory cytokines, AD biomarkers, and gut microbiome composition. Twenty-three participants completed the study, including nine APOE4 carriers and fourteen non-carriers. Rapamycin significantly increased CBF in APOE4 carriers, with increases exceeding 15% across multiple brain regions, and improved metabolic and inflammatory profiles with minimal adverse effects. In contrast, non-carriers showed no significant change in CBF and exhibited distinct physiological responses, highlighting genotype dependent effects. These findings suggest that rapamycin may mitigate early cerebrovascular and systemic dysfunction in APOE4 carriers and support a precision medicine approach in which therapeutic response is influenced by genotype.

Why this matters

Rapamycin is one of the noisiest longevity protocols on the consumer radar, but human data remain thin and largely surrogate. A pilot showing that a benefit (cerebral blood flow) may concentrate in a genetic subgroup — APOE4 carriers — is exactly the kind of finding that reframes the trend from ‘universal geroprotector’ to ‘candidate for stratified use,’ and it is the first cerebrovascular readout in that subgroup.

Source

Link

Briefing card

EXPRESS: Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: a pilot single-arm trial.
Stage: trial early · pubmed · 10-sep-2026

If you are a middle-aged APOE4 carrier watching the rapamycin literature, this uncontrolled pilot is the first human signal of a cerebral-blood-flow effect specific to your genotype — not confirmation of cognitive benefit.

Low-dose rapamycin (1 mg/day for 4 weeks) significantly increased cerebral blood flow by over 15% across multiple brain regions and improved metabolic and inflammatory profiles in healthy middle-aged APOE4 carriers, with little CBF effect in non-carriers.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1177/0271678X261490342

build build 880 · 2bcef25 · 2026-11-18